Companies › Suzhou Ribo Life Science
2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RBD2080 Complement inhibitor | – | Phase 1 | Healthy | Sep 2027 |
| RBD1119 | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07042594 | RBD1119 | Phase 1 | Healthy Volunteers | Other | Aug 2026 |
| NCT07869940 | RBD2080 | Phase 1 | Healthy | Other | Sep 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.